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Since the beginning of population screening for CF carriers, it has become apparent that complex CFTR alleles are not uncommon.
Deciphering their impact in disease pathogenesis remains a challenge for both clinicians and researchers. We report the observation of a new
complex allele p.[R74W+R1070W+D1270N] found in trans with a type 1 mutation and associated with clinical diagnosis of cystic fibrosis in
a one year-old Moroccan patient. This case underlines the difficulties in counseling patients with uncommon mutations and the necessity of
functional studies to evaluate the structure–function relationships, since the association of several variations in cis can dramatically alter
CFTR function.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Complex allele; R74W; D1270N; R1070W; CFTR; Cystic fibrosis1. Introduction
More than 1700 cystic fibrosis transmembrane conductance
regulator gene (CFTR) mutations and polymorphisms are
currently reported in the CFTR mutation database [1]. Although
commercial kits are available to identify the most frequent
cystic fibrosis (CF) mutations, most known mutations appear at
frequencies below 0.1% or represent private mutations. In
addition, a significant percentage of CF mutant alleles (ranging
from 2 to 10%) still remains unidentified in CF patients [2].
Since the beginning of population screening for CF carriers, it
has become apparent that complex alleles such as [R74W;
D1270N] (HGVS nomenclature: c.[220CNT;3808GNA]) are
not uncommon [3,4]. Complex alleles are thought to affect the
expression of the phenotype by modulating the effect of
mutations [5–9] but further data are needed to clarify their⁎ Corresponding author. Tel.: +41 21 314 33 71; fax: +41 21 314 33 92.
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allele [R74W;R1070W;D1270N] associated with cystic fibrosis
in a patient from a Moroccan family.
2. Case report
The patient is the first female child of a Moroccan non-
consanguineous couple. Family history is unremarkable and
notably there is no known CF case. She was born at term after an
uneventful pregnancy and weighed 3780 g (P75–P90) for 48 cm
height (P3–P10). She presented feeding difficulties and
vomiting since birth. She was hospitalized in Morocco at the
age of 3 months for dehydration, signs of malnutrition and
diarrhoea. After rehydration, biological analyses revealed
hyponatremia, hypochloremia and hypercalcemia with elevated
natriuria. Back in Switzerland, she was hospitalized for
gastroenteritis and malnutrition. Cow's milk protein intolerance
was ruled out and cystic fibrosis was suspected. Sweat
conductivity measurements (Nanoduct Neonatal Sweat Analysisd by Elsevier B.V. All rights reserved.
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(sweat production 3.3 g/m2/min) and 89 mmol/L (sweat pro-
duction 6.7 g/m2/min). At that time the sweat chloride test did
not allow to collect sufficient amount of sweat. A treatment with
pancreatic enzymes (Creon) was started to support weight gain
although she presented no pancreatic insufficiency (pancreatic
elastase values at 360–380 mcg/g and normal ultrasonography).
Metabolic alkalosis was treated by NaCl administration (4 mEq/
kg/j). One month later, the patient was rehospitalized for a
clinical and radiological picture of pneumonia. Throat swab
culture remained negative.
The conventional sweat chloride test was repeated at the age
of 9 months, allowing to collect 54 μL of sweat: chloride value
was 44 mmol/L, in the intermediate range. Sodium value was
40 mmol/L and the sweat Na:Cl ratio was 0.91. She is followed
by the specialized cystic fibrosis consultation and benefits from
physiotherapy. During follow-up, several episodes of rhinor-
rhea were reported and throat swab culture showed the presence
of Hemophilus influenzae. Creon has been stopped when she
was one year-old. Pancreatic elastase is measured every three
months and remains in the normal range. At 13 months her
growth curve follows P10–P25 for weight and P50–P75 for
height. The patient's evolution under medical supervision is
compatible with symptomatic CF.
Molecular analysis using a commercial kit (INNO-LiPA,
Innogenetics, Ghent, Belgium) identified the heterozygous type
I splice-site mutation 711+1GNT (HGVS nomenclature: c.579-
1GNT). Analysis of the entire coding sequence of the gene was
performed in order to find the presumed second mutation. This
search confirmed the previous result and found three further
CFTR variants in heterozygosity. Segregation analysis showed
the father to be a carrier of 711+1GNT, and the mother of a
complex allele [R74W;R1070W;D1270N] (HGVS: c.[220CNT;
3208CNT; 3808GNA]), confirming our patient as a compound
heterozygote.
3. Discussion
Here we report a new complex allele [R74W;R1070W;
D1270N] in trans with a type I CFTR mutation in a patient with
clinical diagnosis of CF and elevated sweat conductivity
measurements. Nevertheless, sweat chloride test is in the
equivoqual range and molecular analysis identified a new CF
complex allele of unknown significance.
The sweat chloride test remains the gold standard for CF
diagnosis but does not always give a clear answer [10].
Guidelines from the Cystic Fibrosis Foundation Consensus
Report established that sweat chloride values ≥40 mmol/L in
individuals over age 6 months should be considered beyond the
normal range and merit further evaluation [10].
In our case, although sweat test did not allow to confirm
diagnosis, the Na:Cl ratio b1 is supportive of a diagnosis of CF
in children [11]. Moreover, a recent Swiss study comparing
conductivity sweat test versus chloride concentration test
concluded that conductivity test measurement N80 mmol/L
allowed CF diagnosis with a good sensibility and sensitivity
[12].Since CF is associated with a wide range of disease states, it
is extremely difficult to predict the phenotype for newly
identified mutations. The association of mild CFTR mutations
or variants in cis may have a more deleterious effect than each
mutation alone [7]. Yet, the effect of most complex alleles
remains controversal or unclear in the literature. The double
mutant allele [R74W;D1270N], first described in 1995, was
originally thought to be deleterious, although considered as a
“mild” CFTR mutation responsible for a congenital bilateral
absence of the vas deferens (CBAVD) phenotype [7,13].
However, it has since been found in asymptomatic individuals
and may not be sufficient to cause disease [14]. The same
authors described the triple mutant [R74W;V201M;D1270N]
associated with CBAVD when found in homozygous state or in
trans with a severe CF mutation [14]. More recently, another
group reported healthy male dizygotic twins carrying [R74W;
V201M;D1270N] in trans with F508del, suggesting that this
complex allele is not associated with classical CF [15]. To our
knowledge, R1070W has never been described within a
complex allele. R1070W is considered a mutation of “mild”
pancreatic-sufficient CF or of CFTR-related disease including
CBAVD [1,16]; functional studies have revealed abnormal
localization of CFTR bearing R1070W [16].
It is difficult to evaluate the contribution of each mutation to
the phenotypic expression. Prediction tools such as SIFT,
POLYPHEN fail to account for missense mutations that are
found as complex alleles. In a triple mutant, the variations in cis
can act in concert to alter CFTR function dramatically.
Nevertheless, functional studies will be needed to evaluate the
structure–function relationships.
The patient's phenotype suggests that this novel complex
allele might significantly impair the function of CFTR. Given
the young age of the patient, pancreatic insufficiency in later life
cannot be ruled out. Recently, the prevalence of CF and CF-
related disorders in the Moroccan population was estimated to
be in the range of that found in European populations [17].
Family information and carrier testing within relatives were
therefore recommended and the availability of prenatal
diagnosis during a future pregnancy of the parents or other at-
risk relatives was explained.
Research on new treatments for CF now focuses on
developing new pharmacological approaches to address specific
CFTR dysfunctions, further underlining the importance of
complete CFTR sequencing and confirmation of the inheritance
of mutations from both parents in order to establish proper
diagnosis. Complex alleles and their role in disease pathogen-
esis still remain a challenge for both researchers and clinicians.Conflict of interest
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